Pfizer (NYSE:PFE)‘s stock had its “buy” rating reaffirmed by stock analysts at TheStreet in a report issued on Friday, Stock Ratings News reports.
The analysts wrote, “Pfizer (PFE) has been reiterated by TheStreet Ratings as a buy with a ratings score of A. The company’s strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, solid stock price performance, good cash flow from operations and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income.”
A number of other analysts have also recently weighed in on PFE. Analysts at Thomson Reuters/Verus upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a research note to investors on Monday. Finally, analysts at UBS AG raised their price target on shares of Pfizer from $32.00 to $36.00 in a research note to investors on Wednesday, October 30th. They now have a “buy” rating on the stock. Two research analysts have rated the stock with a sell rating, six have issued a hold rating and thirteen have given a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $31.64.
Shares of Pfizer (NYSE:PFE) opened at 31.88 on Friday. Pfizer has a one year low of $24.63 and a one year high of $32.50. The stock’s 50-day moving average is $30.9 and its 200-day moving average is $29.22. The company has a market cap of $206.6 billion and a price-to-earnings ratio of 8.80.
Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, October 29th. The company reported $0.58 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.56 by $0.02. The company had revenue of $12.64 billion for the quarter, compared to the consensus estimate of $12.69 billion. During the same quarter in the prior year, the company posted $0.53 earnings per share. The company’s quarterly revenue was down 2.4% on a year-over-year basis. On average, analysts predict that Pfizer will post $2.18 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which is scheduled for Tuesday, December 3rd. Stockholders of record on Friday, November 8th will be given a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a yield of 3.01%. The ex-dividend date of this dividend is Wednesday, November 6th.
Pfizer Inc (NYSE:PFE) is a research-based, global biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.